Multitude

Multitude Therapeutics is a clinical-stage biotechnology company specializing in the discovery and development of next-generation antibody-drug conjugates (ADCs) for the treatment of cancer. The company leverages its proprietary MabArray platform for target discovery and its M-SLink linker-payload technology to create highly differentiated therapeutics with improved safety and efficacy profiles. Their pipeline includes several promising candidates targeting validated and novel tumor antigens, with lead programs currently undergoing clinical evaluation in patients with advanced solid tumors. By integrating target discovery with advanced conjugation chemistry, Multitude aims to overcome the limitations of current ADC therapies. The company maintains operations in both Shanghai and California to leverage global talent and resources.